Summary of Use during Lactation

No information is available about vilobelimab during breastfeeding. Because vilobelimab is a large protein molecule with a molecular weight of about 149,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. If the mother is at least 2 weeks postpartum the transfer into milk may be minimized.[1] The manufacturer recommends that breastfeeding be discontinued during vilobelimab use. The half-life of vilobelimab is about 4 days, so it should be mostly eliminated about 2 weeks after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22:350–66. [PubMed: 36931808]

Substance Name

Vilobelimab

CAS Registry Number

2250440-41-4

Drug Class

Breast Feeding

Lactation

Milk, Human

Antibodies, Monoclonal, Humanized

Complement Inactivating Agents